Fenbutyramide

Fenbutyramide

SCHEMBL232920

CCC(C(N)=O)c1ccccc1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.63
LMNA P02545 3/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
CRHBP P24387 2/20 0.50
CRHR2 Q13324 2/20 0.50
KCNQ2 O43526 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
GAA P10253 2/20 0.49
KDM4A O75164 1/20 0.49
BCHE P06276 1/20 0.49
MAPT P10636 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RECQL P46063 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fenbutyramide SCHEMBL1478462 1.00 EPHX1 (0.63) EPHX1LMNAHSD17B10ALDH1A1POLB
Fenbutyramide SCHEMBL1477997 1.00 EPHX1 (0.63) EPHX1LMNAHSD17B10ALDH1A1POLB
Fenbutyramide SCHEMBL15995561 0.98 EPHX1 (0.61) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL4935067 0.85 LMNA (0.61) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL15828137 0.84 LMNA (0.53) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL2183709 0.84 EPHX1 (0.59) EPHX1LMNAHSD17B10KCNQ2SMN1; SMN2
SCHEMBL18098100 0.83 EPHX1 (0.54) EPHX1LMNAHSD17B10ALDH1A1POLB
SCHEMBL1715 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL65737 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP
SCHEMBL20769804 0.83 LMNA (0.59) LMNAHSD17B10ALDH1A1POLBCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1027 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12383624-B2 Cargo delivery system and composition comprising the same SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-08-12 US claimed
WO-2025101731-A1 SGLT1 INHIBITORS FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY LEXICON PHARMACEUTICALS, INC. (US) 2025-05-15 WO claimed
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
CN-115745828-A Method for producing phenylamide 山东新华制药股份有限公司 2023-03-07 CN claimed
CN-115403761-A Polyglycol modified lipid compound and preparation method and application thereof 天津键凯科技有限公司 2022-11-29 CN claimed
CN-114149337-B Novel ionizable lipid for nucleic acid delivery and LNP composition thereof 天津键凯科技有限公司 2022-04-29 CN claimed
CN-109851519-A A method of 2- phenylbutanamides are isolated and purified from phenobarbital production waste residue 山东新华制药股份有限公司 2019-06-07 CN claimed
CN-109734619-A A method of impurity A, C are isolated and purified from phenobarbital production waste residue 山东新华制药股份有限公司 2019-05-10 CN claimed
CN-108699106-A Novel trifluoromethyl propanamide derivative as HTRA1 inhibitor 豪夫迈·罗氏有限公司 2018-10-23 CN claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
US-20040110802-A1 Antibacterial benzoic acid derivatives PHARMACIA & UPJOHN COMPANY 2004-06-10 US claimed
WO-2004018461-A2 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
WO-2004018428-A1 ANTIBACTERIAL BENZOIC ACID DERIVATIVES PHARMACIA & UPJOHN COMPANY LLC (US) 2004-03-04 WO claimed
US-6365186-B1 ADMINISTERING TO PATIENT UNSUBSTITUTED POLYDIALLYLAMINE POLYMER AND CHOLESTEROL-LOWERING AGENT IN THERAPEUTICALLY EFFECTIVE AMOUNT GELTEX PHARMACEUTICALS, INC. 2002-04-02 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000069445-A1 COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5783605-A Helper inducers for differentiation therapy and chemoprevention of cancer KUO SHENG-CHU (TW) 1998-07-21 US claimed
EP-0298758-B1 Hydroquinonylphenyl butyric acid amide derivative SUNTORY LTD (JP) 1995-06-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12383624-B2 Cargo delivery system and composition comprising the same ATG7, SQSTM1, BECN1 EPHX1 4333/4885LMNA 1430/4885HSD17B10 4388/4885
US-20040110802-A1 Antibacterial benzoic acid derivatives GABRD, GABBR1, GABRA1 EPHX1 1803/4885LMNA 3376/4885HSD17B10 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.